In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...

The NOACs studied in the included trials were apixaban, rivaroxaban and dabigatran. All trials used aspirin as the single antiplatelet therapy studied. The main outcomes were major bleeding and ...